Where myasthenia gravis treatment is heading
Myasthenia gravis · Updated Nov 13, 2026
Myasthenia gravis is an autoimmune disease where antibodies block nerve signals to muscles, causing weakness that worsens with use: drooping eyelids, double vision, trouble swallowing or breathing. About 1 in 5,000 people have it. Since 2017 a wave of targeted drugs (complement and FcRn blockers, B-cell drugs) has been approved, and cell therapies may offer lasting remission.
- 155studies open or running
- 35phase 3 trials
- 1,108papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
Inebilizumab approved, including MuSKHappened -4.2 MG-ADL points
MG-ADL improved 4.2 vs 2.2 points; approved December 2025.
-4.2: point MG-ADL change with inebilizumab, vs -2.2 with placebo.
A third FcRn blockerHappened -4.70 MG-ADL points
Nipocalimab improved MG-ADL 4.70 vs 3.25 points.
-4.70: point MG-ADL change with nipocalimab, vs -3.25.
-
6 months
by May 2027
CAR T phase 3 resultsLikely 66.7% responded
Cartesian's AURORA trial of Descartes-08 is expected to report in early 2027.
66.7%: responded at 3 months, vs 27.3% with placebo (subgroup).
-
12 months
by Nov 2027
Oral complement blockerPossible
A 146-person phase 3 of iptacopan, a pill, finishes April 2027.
Head-to-head FcRn comparisonPossible
EPIC compares nipocalimab with efgartigimod directly; due September 2027.
-
3 years
by late 2029
Pills that reset B cellsPossible
Phase 3 trials test remibrutinib (BTK blocker) and oral cladribine; due 2028.
-
5 years
by late 2031
One-time cell therapiesLong shot
CD19 and BCMA CAR T trials aim for lasting remission without ongoing drugs.
The research paths
Cell therapy
66.7% respondedDetails and 2 trialsHide
mRNA and CD19 CAR T cells aiming for drug-free remission.
WatchAURORA results.
FcRn and complement drugs
-4.70 MG-ADL pointsDetails and 3 trialsHide
More options, oral forms and head-to-head comparisons.
WatchEPIC; iptacopan.
B-cell drugs
-4.2 MG-ADL pointsDetails and 2 trialsHide
Antibodies and pills that remove or quiet B cells.
WatchRemibrutinib and cladribine.
Borrowed from other conditions
From Neuromyelitis optica
Inebilizumab
Approved
A CD19 antibody first approved for NMOSD.
From Multiple sclerosis
Cladribine
Phase 3
An oral immune-reset pill used in MS.
From PNH (a blood disorder)
Iptacopan
Phase 3
An oral complement factor B inhibitor.
Open to join now
-
Generalized MG
Oral cladribine
Locations and eligibility → -
Generalized MG
IMVT-1402
Locations and eligibility → -
Generalized MG
Nipocalimab vs efgartigimod
Locations and eligibility → -
Refractory MG
KYV-101 CAR T
Locations and eligibility →
See every recruiting Myasthenia gravis trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
FDA approves inebilizumab for gMG
AChR+ and MuSK+.
Nipocalimab phase 3 published
Lancet Neurology.
Standard treatment today
- Mild or ocularPyridostigmine; low-dose steroids.
- GeneralizedSteroids and steroid-sparing drugs (azathioprine, mycophenolate); thymectomy for AChR+ under 65.
- Not controlledComplement blockers (eculizumab, ravulizumab, zilucoplan), FcRn blockers (efgartigimod, rozanolixizumab, nipocalimab), inebilizumab, rituximab for MuSK.
- CrisisIVIG or plasma exchange in hospital.
How to read this page, and sourcesHow to read this page, and sources
- Many new drugs are approved only for antibody-positive generalized MG; ocular and seronegative MG have fewer options.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Myasthenia gravis trials recruiting now →